

AbbVie oral and poster presentations are highlighted below:

Clinical Remission and Endoscopic Outcomes With Subcutaneous SKYRIZI

Title	Description	Session Details
Efficacy and Safety of Risankizumab Subcutaneous Induction and Maintenance in Patients With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 AFFIRM Study/.	Results from the Phase 3 AFFIRM trial showed subcutaneous risankizumab achieved significantly higher rates of clinical remission and endoscopic response versus placebo at Week 12, with rates of all endpoints remaining numerically higher through Week 24 among clinical responders.	Tuesday, October 13 2:15 PM – 2:25 PM CDT Oral Presentation 37
Comparative Efficacy of Subcutaneous Risankizumab Versus Guselkumab as Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease: An Anchored Matching-Adjusted Indirect Comparison.	New indirect comparative analyses showed subcutaneous risankizumab achieved significantly higher rates of endoscopic response versus guselkumab during induction in patients with moderately to severely active Crohn's disease.	Tuesday, October 13 10:30 AM – 4:00 PM CDT Poster P5748

Multiyear Endoscopic Healing With SKYRIZI in Patients With Complex Disease Characteristics and Prior Treatment Exposure

Title	Description	Session Details
Efficacy of Risankizumab by Crohn's Disease Location: Results From 144 Weeks of the FORTIFY Open-Label Extension Study.	New analyses from the Phase 3 FORTIFY open-label extension study demonstrated sustained clinical and endoscopic outcomes with risankizumab through 144 weeks of treatment across ileal, colonic and ileocolonic Crohn's disease. Clinical and endoscopic remission rates were generally maintained or improved over time across disease locations.	Sunday, October 11 3:30 PM – 7:00 PM CDT Poster P1061
Risankizumab for Fistulizing Crohn's Disease: Post Hoc Analysis of Up to 5 Years of Treatment From the FORTIFY Open-Label Extension.	Data from the Phase 3 FORTIFY open-label extension study showed that 74.5% of patients with fistulizing Crohn's disease achieved no draining fistulas after five years of treatment with risankizumab.	Sunday, October 11 3:30 PM – 7:00 PM CDT Poster P1058
Efficacy of Risankizumab by Crohn's Disease Location Through 148 Weeks of Treatment:	New analyses from the ongoing SEQUENCE study demonstrated durable clinical and endoscopic efficacy with risankizumab through nearly three years of	Sunday, October 11 3:30 PM – 7:00 PM CDT

Results from the SEQUENCE Open-Label Extension Study.	treatment in patients with moderately to severely active Crohn's disease following anti-TNF failure. Endoscopic outcomes among patients with ileal disease continued to improve over time and became comparable to outcomes observed across other disease locations by Week 148.	Poster P1060
Sustained Clinical and Endoscopic Improvements With up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderate to Severe Ulcerative Colitis Regardless of the Number of Prior Advanced Therapy Exposures.	New analyses from the ongoing COMMAND open-label extension study demonstrated sustained clinical and endoscopic improvements with risankizumab through three years of treatment in patients with moderately to severely active ulcerative colitis. Benefits were observed regardless of prior advanced therapy exposure, including among patients with experience across multiple advanced therapies.	Tuesday, October 13 10:30 AM – 4:00 PM CDT Poster P5727

Remission and Endoscopic Response with RINVOQ for Advanced and Difficult-to-Treat Crohn's Disease

Title	Description	Session Details
Real-World Outcomes of Upadacitinib in Fistulizing and Strictureing Crohn's Disease Among Patients in the Veterans Affairs Health System.	Real-world data from the Veterans Affairs health system showed that 93.3% of patients with fistulizing disease and 76.9% of patients with strictureing disease who remained on treatment achieved clinical remission and corticosteroid-free remission with upadacitinib.	Monday, October 12 10:30 AM – 4:15 PM CDT Poster P3482
Real-World Outcomes of Upadacitinib in Isolated Ileal Crohn's Disease Among Patients in the Department of Defense Healthcare System.	New real-world data from the Department of Defense healthcare system demonstrated clinical and endoscopic outcomes with upadacitinib in patients with isolated ileal Crohn's disease. At six months, 57% of patients achieved clinical remission, 58% achieved endoscopic response and 53.6% achieved endoscopic remission.	Tuesday, October 13 2:35 PM – 2:45 PM CDT Oral Presentation 39